Dupixent Lawsuit
What is Dupixent and what is it prescribed for?
Dupixent (dupilumab) is a prescription biologic medication manufactured by Sanofi and Regeneron.
It is FDA-approved for treating moderate-to-severe atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis.
The drug works by blocking interleukin-4 and interleukin-13, proteins involved in inflammatory responses.
Since its FDA approval in 2017, Dupixent has become one of the world's best-selling drugs, generating over $11 billion in annual sales.
What side effects have led to Dupixent lawsuits?
The primary side effect leading to Dupixent lawsuits is cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin lymphoma that affects the skin.
A 2023 study published in JAMA Dermatology found that Dupixent users faced a 4.5 times higher risk of developing CTCL compared to non-users.
The research analyzed data from over 150,000 patients and found a clear correlation between Dupixent use and increased cancer risk.
Types of CTCL linked to Dupixent include mycosis fungoides, Sézary syndrome, and primary cutaneous CD30+ lymphoproliferative disorders.
Learn more about Dupixent side effects
Who qualifies for a Dupixent lawsuit?
You may be eligible to file a claim if you meet the following criteria:
- Used Dupixent for three months or longer
- Diagnosed with cutaneous T-cell lymphoma (CTCL), mycosis fungoides, or Sézary syndrome
- Symptoms appeared 30 days or more after starting Dupixent
- No bankruptcy filings or felony convictions
The first wrongful death lawsuit was filed in October 2025 in the U.S. District Court for the Northern District of Illinois.
Check if you qualify for a Dupixent lawsuit
What compensation can Dupixent victims receive?
Dupixent lawsuit settlements may include compensation for:
- Medical expenses, including diagnosis, treatment, and ongoing care costs
- Lost wages and reduced earning capacity due to illness and treatment
- Pain and suffering from cancer diagnosis and treatment side effects
- Reduced quality of life and loss of enjoyment of activities
- Wrongful death damages for surviving family members
While litigation is in early stages, similar pharmaceutical mass tort cases have resulted in settlements ranging from hundreds of thousands to millions of dollars per plaintiff.
Factors affecting settlement value include severity of diagnosis, duration of Dupixent use, strength of medical documentation, and impact on quality of life.
View estimated Dupixent settlement amounts
How long do Dupixent lawsuits take?
Mass tort pharmaceutical cases typically take 2-4 years from filing to settlement.
However, early filers may be selected for bellwether trials, which can lead to earlier settlements.
Statutes of limitations vary by state but generally range from 1-3 years from the date of diagnosis or discovery of harm.
It is critical to consult with an attorney as soon as possible to preserve your legal rights.
Understand the Dupixent filing process
What evidence do I need for a Dupixent claim?
To support your Dupixent lawsuit, gather the following documentation:
- Medical records showing Dupixent prescription and usage dates
- Pathology reports confirming CTCL diagnosis
- Treatment records and medical bills
- Employment records showing lost wages
- Personal journals documenting symptoms and quality of life impact
Your attorney will work with medical experts to establish causation between Dupixent use and your cancer diagnosis.
Mass tort attorneys work on contingency, meaning you pay nothing unless you win your case.
Zero upfront costs • Confidential consultation • No fee unless you win
References
This information is based on peer-reviewed medical research and court filings:
-
Hasan, I., Parsons, L., Duran, S., & Zinn, Z. (2024). Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. Journal of the American Academy of Dermatology, 91(2), 255-258. View study
-
Mandel, J., Mehta, J., Hafer, R., Ayub, M., Nusrat, F., Yang, H., Porcu, P., & Nikbakht, N. (2024). Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis. Dermatologic Therapy, 2024, 9924306. View study
Information last updated: November 2025